Volkan Tahmaz1,2, Martin H J Wiesen3, Uta Gehlsen1,2, Laura Sauerbier1, Michael E Stern1,4, Udo Holtick5, Birgit Gathof6, Christof Scheid5, Carsten Müller3, Philipp Steven7,8. 1. Division for Dry-eye disease and ocular GvHD, Department of Ophthalmology, University of Cologne Medical Faculty and University Hospital of Cologne, Cologne, Germany. 2. Cluster of Excellence: Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Cologne, Germany. 3. Center of Pharmacology, Department of Therapeutic Drug Monitoring, University Hospital of Cologne, Cologne, Germany. 4. ImmunEyez LLC., Irvine, CA, USA. 5. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany. 6. Institute of Transfusion Medicine, University of Cologne, Cologne, Germany. 7. Division for Dry-eye disease and ocular GvHD, Department of Ophthalmology, University of Cologne Medical Faculty and University Hospital of Cologne, Cologne, Germany. philipp.steven@uk-koeln.de. 8. Cluster of Excellence: Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Cologne, Germany. philipp.steven@uk-koeln.de.
Abstract
PURPOSE: Chronic graft versus host disease is a major consequence after allogeneic stem cell transplantation (allo-SCT) and has great impact on patients' morbidity and mortality. Besides the skin, liver, and intestines, the eyes are most commonly affected, manifesting as severe ocular surface disease. Treatment protocols include topical steroids, cyclosporine, tacrolimus, and ASED. Since these patients often receive systemic immunosuppressant therapy from their oncologists, a topical re-administration of these drugs via ASED with potentially beneficial or harmful effects is possible. The purpose of the study was to determine whether and to which extent systemic immunosuppressants are detectable in ASED. METHODS: A total of 34 samples of ASED from 16 patients with hemato-oncological malignancies after allo-SCT were collected during the manufacturing process and screened for levels of cyclosporine, mycophenolic acid, everolimus, and tacrolimus via liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The study followed the tenets of the Declaration of Helsinki and informed consent was obtained from the subjects after explanation of the nature and possible consequences of the study. RESULTS: Cyclosporine was found in 18 ASED samples in concentrations ranging from 6.5-105.0 ng/ml (32.0 ± 22.8 ng/ml, mean ± SD). The concentration range of mycophenolic acid in 19 samples was 0.04-25.0 mg/l (4.0 ± 5.4 mg/l, mean ± SD). Everolimus and tacrolimus concentrations were well below the respective limits of quantification (< 0.6 and < 0.5 ng/ml) of the established LC-MS/MS method in all samples. CONCLUSIONS: Our study suggests that orally administered cyclosporine and mycophenolic acid for the treatment of systemic GvHD, but not everolimus and tacrolimus, are distinctly detectable in ASED in relevant concentrations. It is highly likely that these agents affect topical therapy of ocular GvHD. However, the extent of this effect needs to be evaluated in further studies.
PURPOSE:Chronic graft versus host disease is a major consequence after allogeneic stem cell transplantation (allo-SCT) and has great impact on patients' morbidity and mortality. Besides the skin, liver, and intestines, the eyes are most commonly affected, manifesting as severe ocular surface disease. Treatment protocols include topical steroids, cyclosporine, tacrolimus, and ASED. Since these patients often receive systemic immunosuppressant therapy from their oncologists, a topical re-administration of these drugs via ASED with potentially beneficial or harmful effects is possible. The purpose of the study was to determine whether and to which extent systemic immunosuppressants are detectable in ASED. METHODS: A total of 34 samples of ASED from 16 patients with hemato-oncological malignancies after allo-SCT were collected during the manufacturing process and screened for levels of cyclosporine, mycophenolic acid, everolimus, and tacrolimus via liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The study followed the tenets of the Declaration of Helsinki and informed consent was obtained from the subjects after explanation of the nature and possible consequences of the study. RESULTS:Cyclosporine was found in 18 ASED samples in concentrations ranging from 6.5-105.0 ng/ml (32.0 ± 22.8 ng/ml, mean ± SD). The concentration range of mycophenolic acid in 19 samples was 0.04-25.0 mg/l (4.0 ± 5.4 mg/l, mean ± SD). Everolimus and tacrolimus concentrations were well below the respective limits of quantification (< 0.6 and < 0.5 ng/ml) of the established LC-MS/MS method in all samples. CONCLUSIONS: Our study suggests that orally administered cyclosporine and mycophenolic acid for the treatment of systemic GvHD, but not everolimus and tacrolimus, are distinctly detectable in ASED in relevant concentrations. It is highly likely that these agents affect topical therapy of ocular GvHD. However, the extent of this effect needs to be evaluated in further studies.
Entities:
Keywords:
Autologous serum eye drops; Graft-versus-host disease; Immunosuppression; mass spectrometry
Authors: Y Ogawa; S Okamoto; T Mori; M Yamada; Y Mashima; R Watanabe; M Kuwana; K Tsubota; Y Ikeda; Y Oguchi Journal: Bone Marrow Transplant Date: 2003-04 Impact factor: 5.483
Authors: Tulio B Abud; Francisco Amparo; Ujwala S Saboo; Antonio Di Zazzo; Thomas H Dohlman; Joseph B Ciolino; Pedram Hamrah; Reza Dana Journal: Ophthalmology Date: 2016-04-13 Impact factor: 12.079
Authors: L A Engel; S Wittig; F Bock; L Sauerbier; C Scheid; U Holtick; J-M Chemnitz; M Hallek; C Cursiefen; P Steven Journal: Bone Marrow Transplant Date: 2015-04-20 Impact factor: 5.483
Authors: Yasunori Ichiki; Christopher L Bowlus; Shinji Shimoda; Hiromi Ishibashi; John M Vierling; M Eric Gershwin Journal: Autoimmun Rev Date: 2005-04-21 Impact factor: 9.754
Authors: Yoshihiro Inamoto; Yi-Chen Sun; Mary E D Flowers; Paul A Carpenter; Paul J Martin; Peng Li; Ruikang Wang; Xiaoyu Chai; Barry E Storer; Tueng T Shen; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2015-07-17 Impact factor: 5.742